Pulmonary Fibrosis News and Research

RSS

Rheumatoid arthritis linked to other diseases before and after diagnosis, shows study

A Mayo Clinic-led study involving 3,276 patients has found that people with inflammatory bowel disease, Type 1 diabetes or blood clots may be at increased risk of developing rheumatoid arthritis.

20 Nov 2019

Yale-led study provides roadmap to discover new treatment for idiopathic pulmonary fibrosis

A Yale-led collaborative study boosts scientific understanding of how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, providing a roadmap for researchers to discover new treatment targets for the disease.

15 Nov 2019

UAB study suggests potential treatment target for IPF

Long-held dogma says lung fibrosis in diseases like idiopathic pulmonary fibrosis, or IPF, results from recurrent injury to alveolar epithelium that is followed by dysregulated repair.

12 Nov 2019

The air ambulance billed more than his surgeon did for a lung transplant

Before his double lung transplant, Tom Saputo thought he had anticipated every possible outcome.

6 Nov 2019

New way to slow and reverse fibrosis identified

In cell and mouse models, Mayo Clinic researchers and collaborators have identified a way to slow and reverse the process of uncontrolled internal scarring, called fibrosis.

30 Oct 2019

Researchers identify genetic mutation that causes idiopathic pulmonary fibrosis

Researchers in Japan have identified a genetic mutation that causes a severe lung disease called idiopathic pulmonary fibrosis by killing the cells lining the lung's airways.

10 Oct 2019

UD engineering professor receives NIH grant to accelerate study of lung fibrosis

University of Delaware Professor April Kloxin has been awarded a National Institutes of Health Director's New Innovator Award from the NIH Common Fund's High-Risk, High-Reward Research program, which supports highly innovative research proposals.

9 Oct 2019

Researchers identify new targets to treat fibrotic diseases

When it comes to repairing injured tissue, specialized cells in the body known as fibroblasts are called into action. Fibroblasts give rise to healing cells called myofibroblasts, which generally is good in the short term - but bad when myofibroblast activation gets out of hand.

4 Oct 2019

Nintedanib drug can benefit patients with broad range of scarring lung diseases

Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases.

30 Sep 2019

Gene coding error likely responsible for rare form of inherited 'short telomere' disease

By combing through the entire genetic sequences of a person with a lung scarring disease and 13 of the person’s relatives, Johns Hopkins Medicine researchers say they have found a coding error in a single gene that is likely responsible for a rare form of the disease and the abnormally short protective DNA caps on chromosomes long associated with it.

From Johns Hopkins Medicine 11 Sep 2019

FDA approves first drug to treat patients with rare lung condition

The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.

7 Sep 2019

Rare inherited enzyme disorder offers new clues about fibrotic conditions

What can a family of rare inherited disorders teach scientists about more common health problems like fibrosis? Plenty, based on research led by St. Jude Children's Research Hospital scientists that appears today in the journal Science Advances.

17 Jul 2019

UIC researchers aim to find how mining dusts contribute to black lung disease

Rates of severe coal workers' pneumoconiosis - also known as black lung disease - among coal miners have been on the rise recently despite regulations on exposure to dusts associated with mining.

9 Jul 2019

New target identified for treatment of idiopathic pulmonary fibrosis

An article published in Experimental Biology and Medicine (Volume 244, Issue 9, June 2019) (https://journals.sagepub.com/doi/pdf/10.1177/1535370219843827) identifies a new target for the treatment of idiopathic pulmonary fibrosis.

29 Jun 2019

New statement highlights occupational burden of non-cancerous lung diseases

More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of inhaling vapors, gas, dust or fumes at work, according to a joint American Thoracic Society and the European Respiratory Society statement published in the ATS’s American Journal of Respiratory and Critical Care Medicine.

3 Jun 2019

New chip-sized microscope focuses on super-resolution viewing

An EU-funded project is developing a super-resolution microscope small enough to fit on to a computer chip that can be used to see changes in living cells in real time.

28 May 2019

Framingham Heart Study receives $38 million for the next six years

The Framingham Heart Study, the nation's longest running cohort study with longitudinal analysis of cardiovascular disease, has been renewed for an additional six years and $38 million dollars from the National Heart, Lung, and Blood Institute.

16 Apr 2019

Research could provide a new way to treat organ scarring in future

The increased deposition of connective tissue is a problem in chronic diseases of many organs such as the lungs, liver, kidneys, gut, and the skin.

6 Feb 2019

Study uncovers new clues to lung transplant rejection

A lung transplant often remains the only option for many patients with end-stage lung disease, a condition that can be brought on by emphysema, pulmonary fibrosis, cystic fibrosis and other lung disorders.

4 Feb 2019

The T2B Infrastructure Center for Respiratory Disease set to enter into the final phase

The Korea Institute of Toxicology (KIT·Chief Dr. Song, Chang-woo) National Center for Efficacy Evaluation of Respiratory Disease Product (NCER·Chief Dr. Lee, Kyu-hong) obtained on January 10 the final decision from the Ministry of Health and Welfare that the T2B Infrastructure Center for Respiratory Disease would enter into the final phase (second phase) with funding of 3 billion KRW over two years.

4 Feb 2019